Navigation Links
CoLucid Pharmaceuticals to Present at Sofinnova Japan Biopharma Partnering Conference on Tuesday, October 4th in Tokyo, Japan
Date:9/29/2011

DURHAM, N.C., Sept. 29, 2011 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today that its Chief Executive Officer, Thomas P. Mathers, will be making a company presentation at the Sofinnova Japan Biopharma Partnering Conference at 9:35 – 10:00 a.m. on Tuesday, October 4th, 2011 in the Nami room at the Conrad Hotel in Tokyo, Japan. The partnering meeting is expected to attract over 300 participants from around the globe including business development executives from pharmaceutical companies and investors.

The Company is speaking with potential partners and is interacting with the FDA, and plans to advance its lead program, lasmiditan, for the treatment of acute migraine with or without aura, into pivotal studies in 2012.

About Lasmiditan

Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies.  Lasmiditan is a member of a novel chemical class called "ditans" and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal pathway.  Lasmiditan does not interact with vasoconstrictor 5-HT1B/1D receptors activated by triptans.

Five clinical studies have been successfully completed outside of the U.S., including a Phase 2b double blind placebo controlled oral dose ranging study treating a single migraine attack which was completed in 2010. In the Phase 2b study, lasmiditan achieved its primary endpoint of reducing a moderate or severe headache at baseline to mild or none 2 hours after dosing (p<0.0001) in 391 patients. Differentiation of individual doses from placebo was seen as early as 30 minutes after dosing. Lasmiditan also achieved secondary endpoints, including relief of nausea, photophobia and phonophobia.  Importantly, because there was no evidence of drug-related cardiovascular effects or chest symptoms in the previous five clinical studies, CoLucid expects the pivotal Phase 3 studies to confirm that lasmiditan's side effect profile is highly differentiated from triptans and ergotamines.

About CoLucid Pharmaceuticals, Inc.

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes lasmiditan, a novel treatment for migraine headache, COL-204 for wake promotion, and a conjugated stigmine platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. For more information, please visit CoLucid at www.colucid.com.


'/>"/>
SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million
2. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
3. CoLucid Appoints Thomas P. Mathers as Chief Executive Officer
4. Top 450 Biotechnology (Pharmaceuticals) Report (Global)
5. McNEIL-PPC, Inc. Acquires Full Ownership of the Johnson & Johnson-Merck Consumer Pharmaceuticals Co. Joint Venture
6. Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma
7. Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
8. Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
9. AcelRx Pharmaceuticals Appoints Mark G. Edwards To Its Board of Directors
10. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
11. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , 8 de dezembro de 2016  A Mederi Therapeutics Inc ... Stretta, um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and broadcast ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
(Date:12/8/2016)... AMSTERDAM , December 8, 2016 Information ... TM metrics in Scopus , the world,s largest ... free access to comprehensive metrics for journals from over 5,000 publishers. ... publish, which journals to subscribe to and when to adjust a ... , , ...
Breaking Medicine Technology:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... planning services from offices headquartered in Jefferson County, is announcing the launch of ... in Birmingham. , The number of homeless women and children in Birmingham has ...
(Date:12/8/2016)... Payne, AL (PRWEB) , ... December 08, 2016 ... ... offering insurance and financial consulting services to residential and commercial clients in the ... awareness and support for Nobis Works. , Since 1977, Nobis Works has built ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... celebrating the passage of the most comprehensive mental health systems reform legislation in ... support of the President, and the commitment of our elected officials to improving ...
(Date:12/7/2016)... LAKE CITY, UTAH (PRWEB) , ... December 07, ... ... productivity, today announced the release of Smart Device Remote Control through a new ... management across all platforms and strengthens its mobile solutions to help businesses maximize ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any lab to ... analyzed data. The team at Beckman Coulter has designed Kaluza, templates with advanced analytical ... the need to operate in a GLP (Good Laboratory Practice) fashion. , With features ...
Breaking Medicine News(10 mins):